Dr. Elizabeth Gray joined Ontario Genomics in 2023. In her current role, she provides leadership to a funding initiative aimed at supporting SMEs in health, cleantech and agri-food sectors seeking to commercialize genomics and engineering biology research and technologies, ultimately bringing innovative solutions to the Canadian and International markets.
Elizabeth brings 10 years of progressive leadership experience to this role, having worked in both the public and private sectors. Prior to joining Ontario Genomics, Elizabeth was a VP at a healthcare investment firm, DRI Capital. She also held progressive positions at Eli Lilly Canada, working in both the commercial and medical divisions. Notably, Elizabeth was the Medical Director, Neuroscience, where she built the medical team and launched products in the neuroscience portfolio, from regulatory submissions, to launch readiness and post launch activities. Elizabeth also worked at CCRM (Center for Commercialization of Regenerative Medicine) and CAMH (Center for Addiction and Mental Health), where she evaluated early-stage technologies for their commercialization potential and participated in fund raising activities.
She received her PhD from the University of Toronto, Department of Molecular Genetics and focused on neuronal cell signaling. Her MSc is from McGill University, Department of Plant Science and focused on plant- microbial signaling, whereby she discovered a novel bacteriocin.